Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects

Hereditary dysfibrinogenemia is a rare clotting disorder, which results from mutations in at least one of the three fibrinogen genes. We examined the frequency of hemostatic clinical and laboratory anomalies at presentation of 37 probands from 12 unrelated families with five different defects (Aα R16C, γ A357T, γ318-319 del, γ M310T, and Aα R16S), among. The median age was 51 years (11–86 years). Among 62% who were women three (13%) had experienced one or more spontaneous abortion. More than half of the probands had experienced one or more undue bleeding episode, easy bruising being by far the most common. In 19% of probands (9/37, all above age of 50 years), had experienced at least one episode of arterial or venous thrombosis. Among these, were two (7%) with deep venous thrombosis, seven with arterial thrombosis, and five (14%) had experienced both. We propose that the higher frequency of prolonged PT than aPTT, in ours and in other reported studies, reflects the polymerization delay, which in aPTT is attenuated owing to contact activation prior to calcium addition.

[1]  D. Galanakis,et al.  Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy , 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[2]  D. Farrell,et al.  The fibrinogen Aα R16C mutation results in fibrinolytic resistance , 2006 .

[3]  J. Weisel.  Fibrinogen and fibrin. , 2005, Advances in protein chemistry.

[4]  T. Stinchcombe,et al.  The dysfibrinogenaemias , 2001, British journal of haematology.

[5]  M. Hanss,et al.  A Database for Human Fibrinogen Variants , 2001, Annals of the New York Academy of Sciences.

[6]  H. Lill,et al.  Confirmation of mendelian properties of heterodimeric fibrinogen molecules in a heterozygotic dysfibrinogenemia, "fibrinogen Amarillo," using gprphoresis to differentiate semifibrin molecules from fibrinogen and fibrin. , 2001, Thrombosis research.

[7]  M. Matsuda,et al.  Structure and Function of Fibrinogen: Insights from Dysfibrinogens , 1999, Thrombosis and Haemostasis.

[8]  S. Lord,et al.  γ-Chain Dysfibrinogenemias: Molecular Structure-Function Relationships of Naturally Occurring Mutations in the γ Chain of Human Fibrinogen , 1998 .

[9]  S. Lord,et al.  gamma-Chain dysfibrinogenemias: molecular structure-function relationships of naturally occurring mutations in the gamma chain of human fibrinogen. , 1998, Blood.

[10]  G. Nuovo,et al.  Fibrinogen mRNA and antigen co-present in human trophoblasts in situ: possible implications. , 1996, Thrombosis research.

[11]  D. Galanakis,et al.  The dimeric Aα chain composition of dysfibrinogenemic molecules with mutations at Aα 16 , 1995 .

[12]  M. Samama,et al.  Familial Dysfibrinogenemia and Thrombophilia , 1995, Thrombosis and Haemostasis.

[13]  J. Soria,et al.  Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. , 1993, Blood.

[14]  D. Galanakis,et al.  Unusual A alpha 16Arg-->Cys dysfibrinogenaemic family: absence of normal A alpha-chains in fibrinogen from two of four heterozygous siblings. , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[15]  D. Galanakis.  Inherited Dysfibrinogenemia: Emerging Abnormal Structure Associations With Pathologic and Nonpathologic Dysfunctions , 1993, Seminars in thrombosis and hemostasis.

[16]  M. Mosesson.  Index of Variant Human Fibrinogens , 1991 .

[17]  S. Lord,et al.  A congenitally abnormal fibrinogen (Vlissingen) with a 6-base deletion in the gamma-chain gene, causing defective calcium binding and impaired fibrin polymerization. , 1991, The Journal of biological chemistry.

[18]  A. Henschen,et al.  Fibrinogen Stony Brook, a heterozygous A alpha 16Arg----Cys dysfibrinogenemia. Evaluation of diminished platelet aggregation support and of enhanced inhibition of fibrin assembly. , 1989, The Journal of clinical investigation.

[19]  J. Soria,et al.  Studies on the ultrastructure of fibrin lacking fibrinopeptide B (beta-fibrin). , 1987, Blood.

[20]  J. Soria,et al.  Fibrinogen Pontoise - a genetically abnormal fibrinogen with defective fibrin polymerisation but normal fibrinopeptide release , 1986 .

[21]  C. Southan,et al.  Genetically abnormal fibrinogens - some current characterisation strategies , 1983 .

[22]  J. Shainoff,et al.  FIBRINOPEPTIDE B IN FIBRIN ASSEMBLY AND METABOLISM: PHYSIOLOGIC SIGNIFICANCE IN DELAYED RELEASE OF THE PEPTIDE * , 1983, Annals of the New York Academy of Sciences.

[23]  A. Henschen,et al.  Novel structure elucidation strategy for genetically abnormal fibrinogens with incomplete fibrinopeptide release as applied to fibrinogen Schwarzach. , 1983, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[24]  F. Lottspeich,et al.  High-performance liquid chromatography of proteins as applied to fibrinogen chains. , 1982, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[25]  R. Doolittle.  Fibrinogen and fibrin. , 1981, Scientific American.

[26]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .